The constitutive expression of the CD137 ligand has been shown in the serum of patients with B-cell lymphomas (Souza-Fonseca-Guimaraes et al., 2016), which may explain the contribution of this variant to cancer predisposition. This evidence concerns the gene TNFRSF9 and B-cell non-Hodgkin lymphoma.